daurisoline has been researched along with Esophageal Squamous Cell Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Jia, L; Liu, Q; Pan, Y; Wang, F; Xu, T; Yuan, S; Zhang, L | 1 |
| Dong, Z; Jiang, Y; Li, M; Li, X; Liu, K; Lu, J; Wang, D; Wu, Q; Yu, Y; Yuan, Q; Zhang, W; Zhang, X; Zhao, J; Zhao, L | 1 |
2 other study(ies) available for daurisoline and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Daurisoline Inhibits ESCC by Inducing G1 Cell Cycle Arrest and Activating ER Stress to Trigger Noxa-Dependent Intrinsic and CHOP-DR5-Dependent Extrinsic Apoptosis via p-eIF2
Topics: Activating Transcription Factor 4; Animals; Apoptosis; Apoptosis Regulatory Proteins; Benzylisoquinolines; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Eukaryotic Initiation Factor-2; G1 Phase Cell Cycle Checkpoints; Humans; Mice; Reactive Oxygen Species; Signal Transduction | 2022 |
Daurisoline suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting MEK1/2 kinase.
Topics: Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; Molecular Docking Simulation; Xenograft Model Antitumor Assays | 2023 |